LOU Zhenbang
,
WANG Kang
,
CHENG Yuqiang
,
YU Hongming
,
CHENG Shuqun
. New progression in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis[J]. Surgical Research and New Technique, 2023
, 12(3)
: 157
-162
.
DOI: 10.3969/j.issn.2095-378X.2023.03.001
[1] Ferlay J, Colombet M, Soerjomataram I, et al.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-1953.
[2] Llovet JM, Kelley RK,Villanueva A, et al.Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6.
[3] Katagiri S, Yamamoto M.Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J].Surg Today, 2014, 44(2): 219-226.
[4] Cheng SQ, Wu MC, Chen H, et al.Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein[J]. Hepatogastroenterology, 2007, 54(74): 499-502.
[5] Kudo M, Izumi N, Kubo S, et al.Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan[J]. Hepatol Res, 2020, 50(1): 15-46.
[6] Lau WY,Wang K, Zhang XP,et al.A new staging system for hepatocellular carcinoma associated with portal vein tumor thrombus[J]. Hepatobiliary Surg Nutr,2021, 10(6): 782-795.
[7] Sun J,Guo R, Bi X, et al.Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 Edition)[J]. Liver Cancer, 2022, 11(4): 315-328.
[8] EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[9] Chen ZH,Zhang XP, Zhou T, et al.Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis[J]. Eur J Surg Oncol, 2019, 45(11): 2188-2196.
[10] Zhang XP, Chai ZT, Gao Y Z, et al.Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB (Oxford), 2019, 21(12): 1687-1696.
[11] Wei X, Jiang Y, Zhang X, et al.Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol 2019, 37(24): 2141-2151.
[12] Zhang YF, Guo RP, Zou RH, et al.Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study[J]. Eur Radiol 2016, 26(7): 2078-88.
[13] Li S, Zhong C, Li Q, et al.Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial[J]. J Clin Oncol, 2021. 39(15): 4008.
[14] Zhang X, Wang K, Wang M, et al.Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis[J]. Oncotarget, 2017, 8(17): 29416-29427.
[15] Fu Z, Li X, Zhong J, et al.Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study[J]. Hepatol Int, 2021, 15(3): 663-675.
[16] Li XL, Guo WX, Hong XD, et al.Efficacy of the treatment of transarterial chemoembolization combined with radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus: A propensity score analysis[J]. Hepatol Res, 2016, 46(11):1088-1098.
[17] Guo L, Wei X, Feng S, et al.Radiotherapy prior to or after transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a randomized controlled trial[J]. Hepatol Int, 2022, 16(6):1368-1378.
[18] Feng JK, Liu Z H, Fu Z G, et al.Efficacy and safety of transarterial chemoembolization plus antiangiogenic-targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world[J]. Front Oncol, 2022, 25(12): 954203.
[19] Zhang W, Zhang K, Liu C, et al.Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study[J]. Front Immunol, 2023, 26(14): 1127349.
[20] Luo L, Xiao Y, Zhu G, et al.Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience[J]. Front Oncol, 2022,23(12): 1004652.
[21] Yang X, Chen B, Wang Y, et al.Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients[J]. Hepatol Int, 2023, 17(3): 709-719.
[22] Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[23] Wang K, Xiang YJ, Yu HM, et al.Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study[J]. Front Immunol, 2023, 16(14): 1107542.
[24] Sun J, Liu C, Shi J, et al.A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study[J]. Chin Med J (Engl), 2022, 135(19): 2338-2343.
